StrangeTony,
Gentiva issued $53 million in stock, roughly 4.8 million shares, as part of Harden Healthcare's purchase price. After holding such shares less than two months, Gentiva filed a prospectus for these shareholders to potentially flip their shares.
Should the listed stockholders have sold their shares at today's closing price, they would've made $4.3 million in less than two months. The biggest winner is R. Steven Hicks with over $27 million in proceeds. Hicks is the new Vice Chairman of Gentiva's board.
Senior Executives cut employee PTO across the board in a January 9 Executive Memo, likely with board approval. It will be a Happy New Year for a select few at the top at Gentiva. The rest, not so much.
I appreciate your posting my Gentiva finds on your blog. They've been coming fast and furious. I do want to hear how things are at Generic Hospice. Please tell me greed, arrogance and hubris have not overtaken your company as well. Sincerely,
Anonymous
When hospice reverts to the lowest common denominator and leaders obsess about metrics, it's time to speak. Self-inflated leaders assume clinicians give until their backs break, given no raises for years. A clinical ladder is a rainbow’s pot of gold. Others have a sorrier job and must be motivated by money. Abysmal leaders dangle extrinsic rewards for admission, hiring and EDBITA targets. “Sign on” bonuses entice people into a poor work environment. Employees’ voice equals their raise, zero.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment